NCT01857817 - Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Prostatic Neoplasms

Interventions

DRUG

VT-122

The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.

DRUG

Placebo

The placebo capsules will be prepared to match the active drug.

Trial Locations (16)

10467

Montefiore Medical Center, The Bronx

11530

AccuMed Research Associates, Garden City

12601

Premier Medical Group of the Hudson Valley PC, Poughkeepsie

32207

Baptist Cancer Institute, Jacksonville

34205

Manatee Medical Research Institute, LLC, Bradenton

48201

Karmanos Cancer Institute, Detroit

48912

Detroit Clinical Research Center, PC, Lansing

56377

Adult & Pediatric Urology, Sartell

60099

Midwestern Regional Medical Center, Zion

72703

Highlands Oncology Group, Fayetteville

77030

Oncology Consultants, P.A., Houston

79601

Hendrick Cancer Center, Abilene

80134

Advanced Urology, Parker

95403

Redwood Regional Medical Group, Santa Rosa

98101

Virginia Mason Medical Center, Seattle

99208

Medical Oncology Associates, PS, Spokane